Complexes of Tetraspanins with Integrins: More Than Meets the Eye
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only. -
Machine-Learning and Chemicogenomics Approach Defi Nes and Predicts Cross-Talk of Hippo and MAPK Pathways
Published OnlineFirst November 18, 2020; DOI: 10.1158/2159-8290.CD-20-0706 RESEARCH ARTICLE Machine -Learning and Chemicogenomics Approach Defi nes and Predicts Cross-Talk of Hippo and MAPK Pathways Trang H. Pham 1 , Thijs J. Hagenbeek 1 , Ho-June Lee 1 , Jason Li 2 , Christopher M. Rose 3 , Eva Lin 1 , Mamie Yu 1 , Scott E. Martin1 , Robert Piskol 2 , Jennifer A. Lacap 4 , Deepak Sampath 4 , Victoria C. Pham 3 , Zora Modrusan 5 , Jennie R. Lill3 , Christiaan Klijn 2 , Shiva Malek 1 , Matthew T. Chang 2 , and Anwesha Dey 1 ABSTRACT Hippo pathway dysregulation occurs in multiple cancers through genetic and non- genetic alterations, resulting in translocation of YAP to the nucleus and activation of the TEAD family of transcription factors. Unlike other oncogenic pathways such as RAS, defi ning tumors that are Hippo pathway–dependent is far more complex due to the lack of hotspot genetic alterations. Here, we developed a machine-learning framework to identify a robust, cancer type–agnostic gene expression signature to quantitate Hippo pathway activity and cross-talk as well as predict YAP/TEAD dependency across cancers. Further, through chemical genetic interaction screens and multiomics analyses, we discover a direct interaction between MAPK signaling and TEAD stability such that knockdown of YAP combined with MEK inhibition results in robust inhibition of tumor cell growth in Hippo dysregulated tumors. This multifaceted approach underscores how computational models combined with experimental studies can inform precision medicine approaches including predictive diagnostics and combination strategies. SIGNIFICANCE: An integrated chemicogenomics strategy was developed to identify a lineage- independent signature for the Hippo pathway in cancers. -
Tetraspanin CD53: an Overlooked Regulator of Immune Cell Function
Medical Microbiology and Immunology (2020) 209:545–552 https://doi.org/10.1007/s00430-020-00677-z REVIEW Tetraspanin CD53: an overlooked regulator of immune cell function V. E. Dunlock1 Received: 31 March 2020 / Accepted: 2 May 2020 / Published online: 21 May 2020 © The Author(s) 2020 Abstract Tetraspanins are membrane organizing proteins that play a role in organizing the cell surface through the formation of subcellular domains consisting of tetraspanins and their partner proteins. These complexes are referred to as tetraspanin enriched microdomains (TEMs) or the tetraspanin web. The formation of TEMs allows for the regulation of a variety of cellular processes such as adhesion, migration, signaling, and cell fusion. Tetraspanin CD53 is a member of the tetraspanin superfamily expressed exclusively within the immune compartment. Amongst others, B cells, CD4+ T cells, CD8+ T cells, dendritic cells, macrophages, and natural killer cells have all been found to express high levels of this protein on their sur- face. Almost three decades ago it was reported that patients who lacked CD53 sufered from an increased susceptibility to pathogens resulting in the clinical manifestation of recurrent viral, bacterial, and fungal infections. This clearly suggests a vital and non-redundant role for CD53 in immune function. Yet, despite this striking fnding, the specifc functional roles of CD53 within the immune system have remained elusive. This review aims to provide a concise overview of the published literature concerning CD53 and refect on the underappreciated role of this protein in immune cell regulation and function. Keywords Tetraspanins · Tetraspanin enriched microdomains · CD53 · Membrane organization · Immune cell signaling · Immune cell adhesion Introduction: tetraspanins in the immune surface or on intracellular membranes. -
An Extracellular Site on Tetraspanin CD151 Determines Α3 and Α6
JCBArticle An extracellular site on tetraspanin CD151 determines ␣3 and ␣6 integrin–dependent cellular morphology Alexander R. Kazarov, Xiuwei Yang, Christopher S. Stipp, Bantoo Sehgal, and Martin E. Hemler Dana-Farber Cancer Institute and Department of Pathology, Harvard Medical School, Boston, MA 02115 he ␣31 integrin shows strong, stoichiometric, direct Brij 96–resistant) were independent of the QRD/TS151r lateral association with the tetraspanin CD151. As site, occurred late in biosynthesis, and involved mature T shown here, an extracellular CD151 site (QRD194–196) integrin subunits. Presence of the CD151–QRD194–196→INF is required for strong (i.e., Triton X-100–resistant) ␣31 mutant disrupted ␣3 and ␣6 integrin–dependent formation association and for maintenance of a key CD151 epitope of a network of cellular cables by Cos7 or NIH3T3 cells on (defined by monoclonal antibody TS151r) that is blocked basement membrane Matrigel and markedly altered cell upon ␣3 integrin association. Strong CD151 association spreading. These results provide definitive evidence that with integrin ␣61 also required the QRD194–196 site and strong lateral CD151–integrin association is functionally masked the TS151r epitope. For both ␣3 and ␣6 integrins, important, identify CD151 as a key player during ␣3 and strong QRD/TS151r-dependent CD151 association occurred ␣6 integrin–dependent matrix remodeling and cell spreading, early in biosynthesis and involved ␣ subunit precursor and support a model of CD151 as a transmembrane linker forms. In contrast, weaker associations of CD151 with itself, between extracellular integrin domains and intracellular integrins, or other tetraspanins (Triton X-100–sensitive but cytoskeleton/signaling molecules. -
4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4). -
Supplementary Table 1: Adhesion Genes Data Set
Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like, -
Kruppel-Like Factor 9 Inhibits Glioblastoma Stemness
KRUPPEL-LIKE FACTOR 9 INHIBITS GLIOBLASTOMA STEMNESS THROUGH GLOBAL TRANSCRIPTION REPRESSION AND INHIBITION OF INTEGRIN ALPHA 6 AND CD151 By Jessica Tilghman A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland October, 2015 Abstract Glioblastoma (GBM) stem cells (GSCs) represent tumor-propagating cells with stem-like characteristics (stemness) that contribute disproportionately to GBM drug resistance and tumor recurrence. Understanding the mechanisms supporting GSC stemness is important for developing novel strategies that target tumor propagation to inhibit cancer progression and improve patient survival. Krüppel-like factor 9 (KLF9) has emerged as a regulator of cell differentiation, neural development, and oncogenesis; however, the molecular basis for KLF9’s diverse contextual functions has been unclear. We establish for the first time a genome-wide map of KLF9-regulated targets in human glioblastoma stem-like cells, and show that KLF9 functions as a transcriptional repressor and thereby regulates multiple signaling pathways involved in oncogenesis and regulation of cancer stem-like phenotype. A detailed analysis of two novel KLF9 targets suggests that KLF9 inhibits glioma cell stemness by repressing expression of integrin α6 and CD151. The expression of one candidate KLF9 target gene ITGA6 coding for integrin α6 was verified to be downregulated by KLF9 in GSCs. ITGA6 transcription repression by KLF9 altered GBM neurosphere cell behavior as evidenced by reduced cell adhesion to and migration through membrane coated with the integrin α6 ligand laminin. Forced expression of integrin α6 partially rescued GBM neurosphere cells from the differentiating and adhesion/migration-inhibiting effects of KLF9. -
Human Eosinophils and Their Activation by Allergens Via Danger
Human eosinophils and their activation by allergens via danger signal receptors Elin Redvall ______________________ 2010 Department of Infectious diseases, Institute of Biomedicine, The Sahlgrenska Academy Cover illustration photo: Kerstin Andersson (Eosinophils) Abstract Human eosinophilic granulocytes are polymorphonuclear cells with a powerful arsenal of cytotoxic substances in their granules, which are mainly found in the gastrointestinal mucosa, and the respiratory and genitourinary tracts. Their physiological role is incompletely understood, although it is likely they protect the mucosal surfaces, perhaps by recognizing danger signals present on microorganisms or released from damaged tissue. We have earlier shown that eosinophils can recognize and become directly activated by aeroallergens such as house dust mite (HDM) and birch pollen. Eosinophils exposed to (HDM) release both of the cytotoxic granule proteins eosinophil peroxidase (EPO) and major basic protein, whereas birch pollen extract only triggers EPO release. Here we further investigate which receptors on eosinophils are used to signal the presence of HDM and birch pollen. Recognition was found to be mediated by the formyl peptide receptors (FPRs) FPR1 and FPR2. We also characterized the expression of this family of receptors in human eosinophils and found that they express FPR1 and FPR2, but not FPR3, similar to neutrophilic granulocytes. We also discovered that signaling through FPR1 can desensitize the eotaxin-1 receptor CCR3 rendering the cells anergic with respect to chemotaxis in response to eotaxin-1, but not regarding respiratory burst. Hence, there is cross- talk between these two receptors regarding one important effector function of eosinophils. Eosinophilic reactivity in vitro to the aeroallergens HDM, birch pollen, timothy grass pollen and cat dander did not differ between individuals with allergy and healthy individuals. -
Combination Immunotherapy with Anti-CD20 and Anti-HLA-DR Monoclonal Antibodies Induces Synergistic Anti-Lymphoma Effects in Human Lymphoma Cell Lines
UC Davis UC Davis Previously Published Works Title Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines Permalink https://escholarship.org/uc/item/8pk1f4nx Journal Leukemia & Lymphoma, 48(5) ISSN 1042-8194 Authors Tobin, Evan Denardo, Gerald Zhang, Nan et al. Publication Date 2007-05-01 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Rituximab & ChLym-1 Combined Immunotherapy Combination Immunotherapy with Anti-CD20 and Anti-HLA-DR Monoclonal Antibodies Induces Synergistic Anti-lymphoma Effects in Human Lymphoma Cell Lines Evan Tobin1, Gerald DeNardo1, Nan Zhang2, Alan L. Epstein2, Cathy Liu1 & Sally DeNardo1 1 Department of Internal Medicine, University of California Davis, CA, USA 2 Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA Running Title: Rituximab & ChLym-1 Combined Immunotherapy Keywords: Lymphoma; immunotherapy; rituximab; Lym-1; CD20; HLA-DR 1Address for correspondence: Gerald L. DeNardo, M.D. Division of Hematology and Oncology 1508 Alhambra Blvd., No. 3100 Sacramento, CA 95816 Telephone (916) 734-3787 Fax (916) 703-5014 E-mail: [email protected] 1 Rituximab & ChLym-1 Combined Immunotherapy ABSTRACT Rituximab is effective in about one half of patients with indolent lymphoma. Even these patients relapse and develop rituximab resistance. To increase potency and circumvent resistance, the anti-lymphoma effects of rituximab, an anti-CD20 MAb1, combined with chLym-12, an anti- HLA-DR MAb, were assessed in human lymphoma cell lines by examining growth inhibition and cell death, apoptosis induction, ADCC3 and CDC4. There were additive effects in all assays and synergism in cell lines, such as B35M, which displayed resistance to either MAb alone. -
RT² Profiler PCR Array (Rotor-Gene® Format) Human Cell Surface Markers
RT² Profiler PCR Array (Rotor-Gene® Format) Human Cell Surface Markers Cat. no. 330231 PAHS-055ZR For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Rotor-Gene Q, other Rotor-Gene cyclers Format R Description The Human Cell Surface Markers RT² Profiler PCR Array profiles the expression of 84 genes relevant to research at the cell surface marker level. These markers have been used in studies including: 1) determination of the extent of leukocyte infiltration among cancer tissues; 2) characterization of cell populations isolated from patients with chronic inflammatory diseases such as atherosclerosis, asthma, inflammatory bowel disease, and arthritis; 3) determination of T- and B-cell lineage and clonality; 4) characterization of leukocyte populations for use in the prognosis of disease stage and progression; and 5) analysis of the composition of immune infiltrates and their association with organ rejection. Using real-time PCR, you can easily and reliably analyze expression of a focused panel of genes related to cell surface markers with this array. For further details, consult the RT² Profiler PCR Array Handbook. Shipping and storage RT² Profiler PCR Arrays in the Rotor-Gene format are shipped at ambient temperature, on dry ice, or blue ice packs depending on destination and accompanying products. For long term storage, keep plates at –20°C. Note: Ensure that you have the correct RT² Profiler PCR Array format for your real-time cycler (see table above). Note: Open the package and store the products appropriately immediately on receipt. Sample & Assay Technologies Array layout The 96 real-time assays in the Rotor-Gene format are located in wells 1–96 of the Rotor-Disc™ (plate A1–A12=Rotor-Disc 1–12, plate B1–B12=Rotor-Disc 13–24, etc.). -
CD20 (B9E9): Sc-9984
SAN TA C RUZ BI OTEC HNOL OG Y, INC . CD20 (B9E9): sc-9984 BACKGROUND APPLICATIONS CD20 is a leukocyte surface antigen consisting of four transmembrane regions CD20 (B9E9) is recommended for detection of CD20 of human origin by and cytoplasmic N- and C-termini. The cytoplasmic domain of CD20 contains Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), multiple phosphorylation sites, leading to additional isoforms. CD20 is ex- immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell pressed primarily on B cells but has also been detected on both normal and lysate)] and flow cytometry (1 µg per 1 x 10 6 cells). neoplastic T cells. CD20 functions as a calcium-permeable cation channel, and Suitable for use as control antibody for CD20 siRNA (h): sc-29972, CD20 it is known to accelerate the G to G progression induced by IGF-1. CD20 is 0 1 shRNA Plasmid (h): sc-29972-SH and CD20 shRNA (h) Lentiviral Particles: activated by the IGF-1 receptor via the subunits of the heterotrimeric G α sc-29972-V. proteins. Activation of CD20 significantly increases DNA synthesis and is thought to involve basic helix-loop-helix leucine zipper transcription factors. Molecular Weight of CD20 isoforms: 33-37 kDa. REFERENCES RECOMMENDED SECONDARY REAGENTS 1. Tedder, T.F., et al. 1994. CD20: a regulator of cell-cycle progression of B To ensure optimal results, the following support (secondary) reagents are lymphocytes. Immunol. Today 15: 450-454. recommended: 1) Western Blotting: use goat anti-mouse IgG-HRP: sc-2005 (dilution range: 1:2000-1:32,000) or Cruz Marker™ compatible goat anti- 2. -
Aberrant Expression of Tetraspanin Molecules in B-Cell Chronic Lymphoproliferative Disorders and Its Correlation with Normal B-Cell Maturation
Leukemia (2005) 19, 1376–1383 & 2005 Nature Publishing Group All rights reserved 0887-6924/05 $30.00 www.nature.com/leu Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation S Barrena1,2, J Almeida1,2, M Yunta1,ALo´pez1,2, N Ferna´ndez-Mosteirı´n3, M Giralt3, M Romero4, L Perdiguer5, M Delgado1, A Orfao1,2 and PA Lazo1 1Instituto de Biologı´a Molecular y Celular del Ca´ncer, Centro de Investigacio´n del Ca´ncer, Consejo Superior de Investigaciones Cientı´ficas-Universidad de Salamanca, Salamanca, Spain; 2Servicio de Citometrı´a, Universidad de Salamanca and Hospital Universitario de Salamanca, Salamanca, Spain; 3Servicio de Hematologı´a, Hospital Universitario Miguel Servet, Zaragoza, Spain; 4Hematologı´a-hemoterapia, Hospital Universitario Rı´o Hortega, Valladolid, Spain; and 5Servicio de Hematologı´a, Hospital de Alcan˜iz, Teruel, Spain Tetraspanin proteins form signaling complexes between them On the cell surface, tetraspanin antigens are present either as and with other membrane proteins and modulate cell adhesion free molecules or through interaction with other proteins.25,26 and migration properties. The surface expression of several tetraspanin antigens (CD9, CD37, CD53, CD63, and CD81), and These interacting proteins include other tetraspanins, integri- F 22,27–30F their interacting proteins (CD19, CD21, and HLA-DR) were ns particularly those with the b1 subunit HLA class II 31–33 34,35 analyzed during normal B-cell maturation and compared to a moleculesFeg HLA DR -, CD19, the T-cell recep- group of 67 B-cell neoplasias. Three patterns of tetraspanin tor36,37 and several other members of the immunoglobulin expression were identified in normal B cells.